Smithers PDS to Present Strategies for Speed and Accuracy in Nonclinical Development in Phoenix during ACT 2025
November 16–19, 2025 | JW Marriott Desert Ridge | Phoenix, AZ | Booth #106
Smithers Pharmaceutical Development Services (PDS) is proud to announce its first participation in the American College of Toxicology’s Annual Meeting, taking place November 16–19, 2025, at the JW Marriott Desert Ridge in Phoenix, Arizona. The Smithers PDS team will exhibit at Booth #106, meeting with toxicologists, bioanalytical scientists, and development partners to share insights into accelerating complex biotherapeutic programs through innovative bioanalytical strategies.
A New Venue to Strengthen Preclinical Partnerships
As Smithers expands its role across the drug development continuum, ACT represents an ideal opportunity to connect directly with toxicologists and early-stage drug developers. This year’s presence underscores the group’s growing focus on collaboration earlier in the process—where understanding molecule behavior and method design can significantly streamline the transition from preclinical to clinical stages.
“By working with clients at the earliest stages of bioanalytical method development, we can help them anticipate and overcome challenges that arise later in toxicology and clinical studies,” said Connie Scott, Senior Business Development Manager at Smithers. “Our scientists are deeply experienced in troubleshooting complex assays and meeting critical milestones that matter most to small and mid-tier biotech teams.”
Smithers’ reputation for responsive communication, scientific rigor, and on-time delivery has made it a trusted partner for biopharma organizations seeking dependable support for their nonclinical programs. At ACT, the team looks forward to demonstrating how their agile, science-driven approach helps clients meet aggressive development timelines while ensuring quality and regulatory integrity.
Exhibitor-Hosted Program: A Closer Look at Method Development Excellence
One of the highlights of Smithers’ ACT debut will be an Exhibitor-Hosted Program led by Christina Satterwhite, PhD, President of Smithers Pharmaceutical Development Services: Strategies for Developing High Quality Bioanalytical Methods with Speed and Accuracy to Support Nonclinical Program Timelines
📅 Sunday, November 16, 2025
🕛 12:00 PM – 12:55 PM
📍 Grand Sonoran K, JW Marriott Desert Ridge
This 55-minute session will explore the growing complexity of modern biotherapeutics—many of which target multiple distinct epitopes—and the corresponding challenges this poses for bioanalytical method development and validation. Dr. Satterwhite will discuss key scientific and operational strategies to ensure the delivery of high-quality, on-time data that supports effective decision-making and regulatory compliance throughout drug development.
For small and mid-sized biotech companies, where timelines are often tightly linked to investor milestones, the ability to generate reliable, decision-enabling data efficiently can make a critical difference. The session will highlight real-world approaches that balance speed, scientific quality, and regulatory readiness in nonclinical method development.
Visit Smithers PDS at Booth #106
Throughout the conference, attendees are invited to visit the Smithers PDS booth to meet the team, discuss upcoming projects, and explore how Smithers’ end-to-end bioanalytical services can accelerate progress in both nonclinical and clinical programs. With expertise spanning PK/TK, immunogenicity, biomarkers, and molecular biology, the group offers tailored solutions to meet the unique needs of biologics and emerging modalities.
“ACT is the perfect environment to engage with our peers, stay current on new trends, and connect with sponsors who share our commitment to advancing safe and effective therapeutics,” added Scott. “We’re excited to be part of this year’s event and to share how Smithers’ approach is helping clients move science forward—faster.”
